ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Purpose: DNA-damaging agents comprise the backbone of systemic treatment for many tumor types; however, few reliable predictive biomarkers are available to guide use of these agents. In muscle-invasive bladder cancer (MIBC), cisplatin-based chemotherapy improves survival, yet response varies widely among patients. Here, we sought to define the role of the nucleotide excision repair (NER) gene ERCC2 as a biomarker predictive of response to cisplatin in MIBC. Experimental Design: Somatic missense mutations in ERCC2 are associated with improved response to cisplatin-based chemotherapy; however, clinically identified ERCC2 mutations are distributed throughout the gene, and the impact of individual ERCC2 variants on NER capacity and cisplatin sensitivity is unknown. We developed a microscopy-based NER assay to profile ERCC2 mutations observed retrospectively in prior studies and prospectively within the context of an institution-wide tumor profiling initiative. In addition, we created the first ERCC2-deficient bladder cancer preclinical model for studying the impact of ERCC2 loss of function. Results: We used our functional assay to test the NER capacity of clinically observed ERCC2 mutations and found that most ERCC2 helicase domain mutations cannot support NER. Furthermore, we show that introducing an ERCC2 mutation into a bladder cancer cell line abrogates NER activity and is sufficient to drive cisplatin sensitivity in an orthotopic xenograft model. Conclusions: Our data support a direct role for ERCC2 mutations in driving cisplatin response, define the functional landscape of ERCC2 mutations in bladder cancer, and provide an opportunity to apply combined genomic and functional approaches to prospectively guide therapy decisions in bladder cancer. See related commentary by Grivas, p. 907
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 3×
“Cohort characteristics and genomic analyses A pan-cancer analysis of ERCC2 mutations was performed by identifying all ERCC2 missense mutations from an institutional analysis of 10,919 tumors (15).”
MethodInfluentialSelf-citationMolecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · cited 1×
“pathway, or a drug efflux pump may be responsible for mediating cisplatin resistance.[29] Further work aimed at understanding the molecular underpinnings of incomplete response in these outlier cases may provide broader insights regarding mechanisms of resistance to DNA-”
BackgroundUnderstanding nucleotide excision repair and its roles in cancer and ageing
Marteijn, J. A., Lans, H., Vermeulen, W., & Hoeijmakers, J. H. J. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3822 · Cited by 1,192 · cited 1×
“ERCC2 is a DNA helicase and a member of the nucleotide excision repair (NER) pathway, which repairs intrastrand crosslinks created by genotoxins such as UV irradiation and platinum chemotherapies (12).”
BackgroundTeo, M. Y., Seier, K., Ostrovnaya, I., Regazzi, A. M., Kania, B. E., Moran, M. M., Cipolla, C. K., Bluth, M. J., Chaim, J., Al-Ahmadie, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7740 · Cited by 544 · cited 2×
“DNA repair deficiency is an important predictive biomarker in several clinical contexts, and DNA repair pathway alterations have recently been associated with increased sensitivity to immune checkpoint blockade in bladder cancer and other tumor types (10, 11, 30), providing further motivation to characterize the funct…”
BackgroundSelf-citation
Cited by
The rediscovery of platinum-based cancer therapy
Rottenberg, S., Disler, C., & Perego, P. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00308-y · Cited by 972
Dyrskjøt, L., Hansel, D. E., Efstathiou, J. A., Knowles, M. A., Galsky, M. D., Teoh, J., & Theodorescu, D. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00468-9 · Cited by 544
A pan-cancer compendium of chromosomal instability
Drews, R. M., Hernando, B., Tarabichi, M., Haase, K., Lesluyes, T., Smith, P. S., Morrill Gavarró, L., Couturier, D.-L., Liu, L., Schneider, M., et al. (2022) · Nature · doi:10.1038/s41586-022-04789-9 · Cited by 294
The current state of molecular testing in the treatment of patients with solid tumors, 2019
El‐Deiry, W. S., Goldberg, R. M., Lenz, H., Shields, A. F., Gibney, G. T., Tan, A. R., Brown, J., Eisenberg, B., Heath, E. I., Phuphanich, S., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21560 · Cited by 264
An Active Learning Framework Improves Tumor Variant Interpretation
Blee, A. M., Li, B., Pecen, T., Meiler, J., Nagel, Z. D., Capra, J. A., & Chazin, W. J. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3798 · Cited by 7
Metadata
- Authors
- Li, Q., Damish, A. W., Frazier, Z., Liu, D., Reznichenko, E., Kamburov, A., Bell, A., Zhao, H., Jordan, E. J., Gao, S. P., Ma, J., Abbosh, P. H., Bellmunt, J., Plimack, E. R., Lazaro, J.-B., Solit, D. B., Bajorin, D., Rosenberg, J. E., D'Andrea, A. D., Riaz, N., Van Allen, E. M., Iyer, G., & Mouw, K. W.
- Venue
- Clinical Cancer Research
- Published
- 2019-02-01
- Volume
- 25
- Issue
- 3
- Pages
- 977-988
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2834512504
- Cited by
- 159
- References
- 6
- FWCI
- 13.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-1001
- The paper
- Li, Q., Damish, A. W., Frazier, Z., Liu, D., Reznichenko, E., Kamburov, A., Bell, A., Zhao, H., Jordan, E. J., Gao, S. P., Ma, J., Abbosh, P. H., Bellmunt, J., Plimack, E. R., Lazaro, J.-B., Solit, D. B., Bajorin, D., Rosenberg, J. E., D'Andrea, A. D., . . . Mouw, K. W. (2019). ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-1001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.